

RECEIVED

JUN 02 2004

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

LALVANI et al

Serial No. 09/308,725

Filed: May 24, 1999

For: ASSAY METHOD FOR PEPTIDE SPECIFIC T-CELLS



Atty. Ref.: 117-310

Group:

Examiner:

RECEIVED
JUL 09 2003
TECH CENTER 1600/2900

RECEIVED

JUN 27 2003

TECH CENTER 1600/2900

* * * * *

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

POWER OF ATTORNEY

The undersigned being the owner of all right, title and interest in the above-identified patent, hereby revokes all previous powers of attorney in this case, and hereby appoints Nixon & Vanderhye, P.C., 1100 North Glebe Rd., 8th Floor, Arlington, VA 22201-4714, telephone number (703) 816-4000, facsimile number (703) 816-4100, and the following attorneys thereof (of the same address) individually and collectively its attorneys to prosecute this application and to transact all business in the Patent and Trademark Office in connection therewith, and with the resulting patent: Arthur R. Crawford, 25327; Larry S. Nixon, 25640; Robert A. Vanderhye, 27076; James T. Hosmer, 30184; Robert W. Faris, 31352; Richard G. Besha, 22770; Mark E. Nusbaum, 32348; Michael J. Keenan, 32106; Bryan H. Davidson, 30251; Stanley C. Spooner, 27393; Leonard C. Mitchard, 29009; Duane M. Byers, 33363; Jeffry H. Nelson, 30481; John R. Lastova, 33149; H. Warren Burnam, Jr. 29366; Thomas E. Byrne, 32205; Mary J. Wilson, 32955; J.

Scott Davidson, 33489; Alan M. Kagen, 36178; Robert A. Molan, 29834; B. J. Sadoff, 36663; James D. Berquist, 34776; Updeep S. Gill, 37334; Michael J. Shea, 34725; Donald L. Jackson, 41090; Michelle N. Lester, 32331; Frank P. Presta, 19828; Joseph S. Presta, 35329; Joseph A. Rhoa, 37515.

Certificate Under 37 C.F.R. §3.73(b)

I hereby certify that ISIS INNOVATION LIMITED of 2 South Parks Road, Oxford OX1 3UB, United Kingdom is the assignee of the entire right, title and interest in the patent application identified above by virtue of an assignment from the inventors to ISIS INNOVATION LIMITED, a copy of that assignment being attached.

I have reviewed the documents in the chain of title of the patent application identified above, and to the best of my knowledge and belief, title is in ISIS INNOVATION LIMITED. I am empowered to act on behalf of ISIS INNOVATION LIMITED.

I declare further that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

ISIS INNOVATION LIMITED

Date:

30 March 2000

T Cook

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

LALVANI et al

Serial No. 09/308,725

Filed: May 24, 1999

Title: ASSAY METHOD FOR PEPTIDE SPECIFIC T-CELLS

Assistant Commissioner for Patents
Washington, DC 20231

Sir:




Atty Dkt. 117-310

C# M#

Group Art Unit:

Examiner:

Date: April 20, 2000

**SUBMISSION**

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

Fees are attached as calculated below:

Total effective claims after amendment 0 minus highest number
previously paid for 20 (at least 20) = 0 x \$ 18.00

Independent claims after amendment 0 minus highest number
previously paid for 3 (at least 3) = 0 x \$ 78.00

If proper multiple dependent claims now added for first time, add \$260.00 (ignore improper)

Petition is hereby made to extend the current due date so as to cover the filing date of this paper and attachment(s) (\$110.00/1 month; \$380.00/2 months; \$870.00/3 months)

Terminal disclaimer enclosed, add \$ 110.00

First submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$690.00)

Second submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$690.00)

☐ Please enter the previously unentered, filed

Subtotal \$ 0.00

If "small entity," then enter half (1/2) of subtotal and subtract

☐ Statement filed herewith

-\$ 0.00

Rule 56 Information Disclosure Statement Filing Fee (\$240.00)

\$ 0.00

Assignment Recording Fee (\$40.00)

\$ 0.00

Other:

0.00

TOTAL FEE ENCLOSED \$ 0.00

The Commissioner is hereby authorized to charge any deficiency in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached.

1100 North Glebe Road, 8th Floor
Arlington, Virginia 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100
MJW:tat

NIXON & VANDERHYE P.C.
By Atty: Mary J. Wilson, Reg. No. 32,955

Signature:

Mary J. Wilson

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

JUN 02 2004

In re Patent Application of

LALVANI et al

Serial No. 09/308,725

Filed: May 24, 1999

Title: ASSAY METHOD FOR PEPTIDE SPECIFIC T-CELLS

Assistant Commissioner for Patents
Washington, DC 20231

Sir:



Atty Dkt. 117-310

C# M#

Group Art Unit:

Examiner:

Date: April 20, 2000

TECH CENTER 1600/2900

RECEIVED

JUN 27 2003

RECEIVED

JUL 09 2003

TECH CENTER 1600/2900

SUBMISSION

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

Fees are attached as calculated below:

Total effective claims after amendment	0	minus highest number		
previously paid for	20	(at least 20) =	0 x \$ 18.00	\$ 0.00
Independent claims after amendment	0	minus highest number		
previously paid for	3	(at least 3) =	0 x \$ 78.00	\$ 0.00
If proper multiple dependent claims now added for first time, add \$260.00 (ignore improper)				\$ 0.00
Petition is hereby made to extend the current due date so as to cover the filing date of this paper and attachment(s) (\$110.00/1 month; \$380.00/2 months; \$870.00/3 months)				\$ 0.00
Terminal disclaimer enclosed, add \$ 110.00				\$ 0.00
First submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$690.00)				\$ 0.00
Second submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$690.00)				\$ 0.00

☐ Please enter the previously unentered , filed

Subtotal \$ 0.00

If "small entity," then enter half (1/2) of subtotal and subtract
☐ Statement filed herewith

Rule 56 Information Disclosure Statement Filing Fee (\$240.00) \$ 0.00

Assignment Recording Fee (\$40.00) \$ 0.00

Other: 0.00


TOTAL FEE ENCLOSED \$ 0.00

The Commissioner is hereby authorized to charge any deficiency in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached.

1100 North Glebe Road, 8th Floor
 Arlington, Virginia 22201-4714
 Telephone: (703) 816-4000
 Facsimile: (703) 816-4100
 MJW:tat

NIXON & VANDERHYE P.C.
 By Atty: Mary J. Wilson, Reg. No. 32,955

Signature:



RECEIVED

JUN 02 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION OF

LALVANI et al

Atty. Ref.: 117-310

Serial No.: 09/308,725

Group Art Unit:

Filed: May 24, 1999

Examiner:

For: ASSAY METHOD FOR PEPTIDE
SPECIFIC T-CELLS

* * * * *

April 20, 2000

SUBMISSION

Hon. Commissioner of Patents
and Trademarks
Washington, DC 20231

Sir:

Submitted herewith is an executed Power of Attorney
relating to the above-identified application.

Respectfully submitted,

NIXON & VANDERHYE, P.C.

By

Mary J. Wilson

Mary J. Wilson
Reg. No. 32,955

MJW:tat

1100 North Glebe Road
8th Floor
Arlington, Virginia 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

RECEIVED
JUN 27 2003
TECH CENTER 1600/2900

RECEIVED
APR 24 2000
TECH CENTER 1600/2900

RECEIVED
JUL 09 2003
TECH CENTER 1600/2900